Monograph
J02AX01 - Flucytosine |
Propably not porphyrinogenic |
PNP |
Rationale
Given in gram doses but probably not significantly metabolised. No data pointing to CYP affinity. Four references state non-porphyrinogenicity.
Chemical description
Antimycotic pyrimidine derivative in systemic use (infusion of 1 g x 4) in sepsis, meningitis, endocarditis etc. Excreted mainly in unchanged form by the kidneys, small amounts converted to fluorouracil. No indications of CYP-interaction. Australian list: safe. EPI-list: safe. South African list: use. French list: use.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Norway
Poland© NAPOS 2024